Judy Mohr, PhD, helps companies maximize product protection and intellectual property (IP) value by focusing on the business goals of the company and designing a patent portfolio to meet those objectives. Her practice encompasses US and non-US patent procurement, post-grant proceedings (including reexamination and inter partes review), IP due diligence on the investor side and the company side, negotiation of agreements, and development of IP strategies. She assists companies in the pharmaceutical, medical diagnostics, medical device, and gas and liquid separations industries.
Drawing on her education in biology, chemistry and chemical engineering, and her decade of industrial experience as an engineer in the polymer and pharmaceutical formulation fields, Judy provides a unique technical background that allows her to quickly assess patent portfolios and provide strategic advice. This is a key advantage in the implementation of patent strategies for pharmaceutical companies, as she is able to understand and communicate the technology to the patent examiners. Judy has worked with companies to develop patent portfolios in the pharmaceutical, drug delivery, diagnostics and water clean-up fields.
Judy has experience counseling emerging and mature life science companies in a broad range of matters, including patentability assessments, freedom to operate analyses, infringement/non-infringement evaluations, and IP due diligence in licensing transactions, financings, mergers and acquisitions. Judy frequently advises her pharmaceutical clients on topics related to Food and Drug Administration (FDA) Orange Book listings and the Hatch-Waxman Act. She also works with the IP litigators and assists clients in patent litigation matters.
Judy earned her doctoral degree in chemical engineering, with a focus in polymer properties and small molecule transport through polymer films, and her bachelor’s degree in biology.
Partner | Silicon Valley
Silicon Valley: +1 650 815 7630
Silicon Valley: +1 650 815 7401
Stanford, CA / Speaking Engagements / February 13, 2019
Stanford, California / Speaking Engagements / February 14, 2018
Stanford, California / Speaking Engagements / February 22, 2017
Menlo Park, California / McDermott Event / January 26, 2017
1
Washington, DC / Press Releases / October 28, 2019
McDermott Recognized for “Standout Client Work” by 2019 LMG Life Sciences Guide
Washington, DC / Accolades & Rankings / June 14, 2019
IAM Patent 1000 Recognizes McDermott Team for Creative Strategies, Clarity of Purpose and ...
Accolades & Rankings / October 3, 2018
McDermott’s Health and Life Sciences Team Earns National Recognitions from LMG ...
Accolades & Rankings / June 13, 2018
McDermott Recognized by IAM Patent 1000 Among Leading Patent Law Practitioners
Düsseldorf / Accolades & Rankings / June 20, 2017
McDermott Maintains Strong Position as a Leading Firm in IAM Patent 1000
Press Releases / December 6, 2016
LMG and Lake Whillans Each Honor McDermott‘s Growing Life Science Practice
Chicago / Accolades & Rankings / July 13, 2016
McDermott Maintains Rankings as a Leading Patent Firm in IAM Patent 1000 2016
Accolades & Rankings / June 24, 2015
McDermott Recommended as a Leading Patent Firm in IAM Patent 1000
Daily Journal / April 22, 2015
Los Angeles / Coverage / April 22, 2015
Daily Journal Names Three McDermott Partners Among “Top 25 Portfolio Managers” for 2015
Daily Journal / March 6, 2015
Patent Prosecutors Face Tougher Tests After Supreme Court Ruling
Washington, DC / Coverage / June 6, 2014
1
2
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.
We use cookies to improve the functionality and performance of this site. By continuing to use this site, you are providing us with your consent to our use of cookies. Please see our Privacy Policy for details.
